Roche’s phase III FENtrepid study of fenebrutinib meets its primary endpoint of non-inferiority compared to Ocrevus in reducing disability progression in patients with PPMS ...

A new AI foundation model from Mass General Brigham may be capable of analyzing brain MRI datasets and predict various ...

Fenebrutinib numerically reduced the risk of disability progression by 12% compared to OCREVUS as early as 24 weeks; additional analysis showed potential benefit in upper limb function Fenebrutinib ...

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, OCREVUS, in reduc ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new late-breaking data from the Phase III FENtrepid study showing the investigational Bruton's tyrosine kinase (BTK ...

Biogen topped fourth-quarter expectations Friday, thanks to far better-than-expected sales of multiple sclerosis treatment ...

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 4 undervalued ...

ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for ...

Losing NINDS director threatens research momentum, AAN says ...

ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease ...

For decades, multiple sclerosis (MS) has been defined primarily by its symptoms, rather than its underlying biology. Now, a ...

BERLIN, Feb 7 (Reuters) - Swiss pharmaceutical company Roche said on Saturday its experimental multiple sclerosis drug ...